Joint Bookrunner on Pharvaris N.V.’s Follow-On Offering

Oppenheimer & Co. Inc. acted as Joint Bookrunner on Pharvaris N.V.’s Upsized $201.2MM Follow-On Offering

Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the closing of its upsized underwritten public offering of 9,562,500 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,312,500 ordinary shares) and pre-funded warrants to purchase 500,000 ordinary shares. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts, commissions and other offering expenses, are approximately $201.2 million.

Pharvaris intends to use the net proceeds of this offering primarily to fund research and development expenses for late-stage clinical programs, the hiring of a sales and marketing team in the U.S. and related commercialization expenses, and for working capital and general corporate purposes.